4//SEC Filing
Mazabraud Yann 4
Accession 0001104659-25-025236
CIK 0001649904other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:16 PM ET
Size
11.3 KB
Accession
0001104659-25-025236
Insider Transaction Report
Form 4
Mazabraud Yann
EVP, Head of International
Transactions
- Exercise/Conversion
Common Stock
2025-03-14$22.28/sh+75,000$1,671,000→ 115,370 total - Sale
Common Stock
2025-03-14$50.79/sh−19,197$975,046→ 96,173 total - Sale
Common Stock
2025-03-14$51.72/sh−55,803$2,886,226→ 40,370 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-03-14−75,000→ 25,000 totalExercise: $22.28Exp: 2030-10-04→ Common Stock (75,000 underlying)
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.31 to $51.26 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $51.31 to $52.04 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The options are fully vested.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001774702
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 9:16 PM ET
- Size
- 11.3 KB